FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 THE AVONEX CHANNEL
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week
March 2005   
April 2005   
June 2005   
July 2005   
August 2005   
September 2005   
October 2005   
November 2005   
May 2006   
June 2006   
July 2006   
October 2006   
April 2010   
May 2013   
June 2013   
July 2013   
August 2013   
July 2014   
November 2014   
January 2015   
February 2015   
April 2015   
July 2015   
January 2016   
March 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Thursday

 

Biogen Tries to Quell Fears About MS Drug Rivals

Biogen Idec (BIIB Quote - Cramer on BIIB - Stock Picks) gathered investors together Wednesday to pitch the company's research pipeline and stifle concerns that its leading position in the multiple sclerosis treatment market was vulnerable to competition.

A phase III study of a long-acting version of Avonex, the company's top-selling multiple sclerosis drug, will begin in the middle of the year, the company announced. The drug, called PEG-Avonex, aims to be more convenient than but equally effective as Avonex, Biogen Idec's most important drug with $2.2 billion in sales last year.

Multiple sclerosis patients will take PEG-Avonex by injection every two weeks or every four weeks instead of the weekly injection required for Avonex.

Biogen Idec also said that patient enrollment has completed in the first of two phase III studies of the company's oral multiple sclerosis drug known as BG-12.

Both BG-12 and PEG-Avonex are important for Biogen Idec's future growth because of competition from Novartis (NVS Quote - Cramer on NVS - Stock Picks) and the German drug maker Merck KGaA, which are developing oral multiple sclerosis drugs of their own.

Both the Novartis drug, known as FTY720, and the Merck drug, cladribine, have posted positive results in phase III studies, and both companies have already announced plans to seek regulatory approval later this year.......full story in The Street.com

Labels: